| COVANCE EXPANDS GLOBAL CLINICAL CARDIOVASCULAR SCIENCES TEAM FOR CENTRALIZED ECG SERVICES |
 |
Princeton, New Jersey, May 19, 2003 — Covance Inc. (NYSE: CVD) announced today the expansion of its global cardiovascular scientific team for centralized ECG services, under the leadership of Dr. Jay W. Mason, a world-renowned cardiologist. Dr. Mason joins Central Diagnostic Services at Covance as full-time Medical Director, based in Reno, Nevada. He is tasked with expanding the unique ECG services that Covance delivers to its pharmaceutical and biotechnology clients and intends to continue his research on repolarization phenomena.
Dr. Mason joins Covance with extensive experience in pharmaceutical clinical trials, including participation as an investigator and as a designer of multi-center, multi-national studies. He is currently chairperson for two National Institutes of Health Data Safety Monitoring Boards and is a consultant to the FDA. Dr. Mason was Chief of Cardiology at the University of Utah for 16 years before becoming Chairman of the Department of Medicine at the University of Kentucky. Trained at Princeton University and The University of Pennsylvania School of Medicine, Dr. Mason is board-certified in internal medicine, cardiovascular diseases, and clinical cardiac electrophysiology.
"Our innovative ECG service combinations for clinical trials are what attracted Dr. Mason to Covance," said Eileen Daniel, Vice President and General Manager of Central Diagnostic Service at Covance. "Over the past 30 years, Covance has created a vast digital ECG database offering opportunities to develop, validate, and quickly implement new methods to better manage cardiac safety questions through accurate and relevant ECG data. We are excited by the potential to further enhance our innovative services under the expertise of Dr. Mason."
Dr. Mason joins Dr. Daniel B. Goodman and Dr. Boaz Mendzelevski, on the Global Cardiovascular Sciences Team at Covance. Dr. Goodman has provided direction on innovative ECG solutions for Covance since 1994, including pioneering Digitography™, the world's first interactive ECG analysis and annotation system for clinical trials. Dr. Mendzelevski, based in London, joined Central Diagnostic Services in February. Most recently, he was Chief Medical Officer for Quintiles Transnational Corp.'s QECG division. He has worked in all stages of drug development, including protocol development, trial monitoring, data acquisition and management, statistical analysis, and medical writing. He has authored more than 120 expert cardiology/QT reports for regulatory submission. Dr. Mendzelevski received his training in Israel at Ben Gurion University Medical School and is board-certified in cardiology and internal medicine. Both Dr. Mendzelevski and Dr. Goodman will be providing full-time safety cardiology consulting to Covance's clients in clinical trials from Phase I through IV.
"Covance has always been an industry leader that invests in the people, processes, and technology to drive scientific quality," said James Bannon, President, Clinical Development, Periapproval, and Central Diagnostic Services. "The addition of renown cardiologists and the expansion of the global cardiovascular leadership team demonstrates that Covance is committed to the importance of cardiac safety and has invested in the fundamental aspects of centralized cardiac safety testing to help our customers make critical drug development decisions."
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with 2002 net revenues of $883 million, global operations in 17 countries, and approximately 6,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through the website in the About Covance area.
Statement contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission. |
|
|
